The company is pleased to inform that the commercialisation of the first Follicopeptide-based product, expected by the end of this year, is firmly on schedule. Commercial scale production is secured in Denmark, and raw material is ordered for the first batches. The regulatory process and negotiations with relevant partner companies are also progressing firmly. 

Coegin Pharma is entering a transformative phase as preparations for the commercialisation of its first Follicopeptide-based product advance according to plan. This milestone marks the company's transformation from an R&D-focused biotech towards a revenue-generating commercial enterprise. Commercial-scale production capabilities have been secured in Denmark, ensuring both product development capacity and full-scale manufacturing. Raw materials have already been ordered, and the bottles will be ordered in the coming weeks. Production of the first commercial batch is set to start in September.

Regulatory preparations are progressing as planned, with the submission of the Product Information File (PIF) scheduled for this autumn - well ahead of the launch. Meanwhile, negotiations with potential partners for initial purchase orders and batch sizing are underway. The EU remains a priority market for the launch, while other markets such as the US, China, South Korea and Brazil are also in focus. The first Follicopeptide product will be delivered in a ready-to-use, attractive bottle, branded by the partner. Potential boxes for the bottles will be tailored to market specific needs.

"This is an incredibly intense and exciting time - we are witnessing a defining moment in Coegin Pharma's history," says Jens Eriksson, CEO of Coegin Pharma. "We are taking the big leap from being a development-stage biotech towards becoming a commercial company with real revenue and cash flow. This is the start of an entirely new chapter for Coegin Pharma, and I look forward to sharing more details about the launch soon."

With production secured, regulatory milestones on track, and commercial discussions accelerating, Coegin Pharma is poised to bring its breakthrough Follicopeptide innovation to market - unlocking a new era of scientifically grounded hair growth solutions.

For further information, please contact:
Jens Eriksson, CEO
Email: info@coeginpharma.com

About Coegin Pharma
Coegin Pharma is a Swedish biotech company developing cutting-edge innovations for hair and skin. The company aims to commercialise a series of hair growth products starting in late 2025, followed by a pigmentation product in 2026.

The company's vision is: "To lead the future of cutting-edge solutions for hair and skin longevity".

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

More information - including subscription to company updates and links to social media - is available at coeginpharma.com

Attached files